公司概覽
業務類別 Biotechnology
業務概覽 Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
公司地址 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
電話號碼 +1 858 558-2871
傳真號碼 +1 858 212-0513
公司網頁 https://www.acadia.com
員工數量 798
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Elizabeth H.Z. Thompson, PhD Executive Vice President and Head of Research and Development 美元 281.88K 25/04/2025
Mr. Thomas A. Garner Executive Vice President and Chief Commercial Officer -- 25/04/2025
Ms. Catherine Owen Adams Director and Chief Executive Officer 美元 245.77K 26/02/2026
Mr. James K. Kihara Senior Vice President, Finance, Controller and Chief Accounting Officer -- 26/02/2026
Mr. Mark C. Schneyer Executive Vice President and Chief Financial Officer 美元 518.47K 26/02/2026
Ms. Jennifer J. Rhodes Executive Vice President, Chief Legal Officer and Secretary 美元 478.03K 25/04/2025
 
董事會成員
董事會 職務 更新日期
Mr. Julian C. Baker Independent Director 26/02/2026
Ms. Laura A. Brege Independent Director 26/02/2026
Mr. James M. Daly Independent Director 26/02/2026
Dr. Stephen R. Biggar,M.D.,PhD Chairman of the Board 26/02/2026
Mr. Jonathan Poole Director 05/03/2026
Dr. Edmund P. Harrigan, M.D. Independent Director 26/02/2026
Ms. Catherine Owen Adams Director and Chief Executive Officer 26/02/2026
Dr. Elizabeth A. Garofalo, M.D. Independent Director 26/02/2026
Dr. Adora Ndu, Pharm.D. Independent Director 26/02/2026
 
所屬ETF (更新日期: 07/03/2026 04:17)
代號 名稱 佔比% 持有日期
SBIOALPS Medical Breakthroughs ETF0.09%27/02/2026
PRFZInvesco RAFI US 1500 Small-Mid ETF0.09%27/02/2026
USVMVictoryShares US Sm Md Cp Val Momt ETF0.09%27/02/2026
LABUDirexion Daily S&P Biotech Bull 3X ETF0.08%26/02/2026
VIOGVanguard S&P Small-Cap 600 Growth ETF0.08%31/01/2026
FNYFirst Trust Mid Cap Growth AlphaDEX® ETF0.08%26/02/2026
FNXFirst Trust Mid Cap Core AlphaDEX® ETF0.08%26/02/2026
VTWGVanguard Russell 2000 Growth ETF0.07%31/01/2026
DFUVDimensional US Marketwide Value ETF0.06%27/02/2026
PSCHInvesco S&P SmallCap Health Care ETF0.06%27/02/2026
GSSCGoldman Sachs ActiveBeta® US SmCp Eq ETF0.05%27/02/2026
VTVanguard Total World Stock ETF0.05%31/01/2026
SCHBSchwab US Broad Market ETF™0.05%28/02/2026
JSMLJanus Henderson Small Cap Gr Alpha ETF0.04%27/02/2026
XSHQInvesco S&P SmallCap Quality ETF0.04%27/02/2026
RZGInvesco S&P SmallCap 600® Pure Gr ETF0.03%27/02/2026
FHLCFidelity MSCI Health Care ETF0.03%28/02/2026
SEISSEI Select Small Cap ETF0.03%27/02/2026
VFQYVanguard US Quality Factor ETF0.03%31/12/2025
BBSCJPMorgan BetaBuilders US Sml Cp Eq ETF0.03%27/02/2026
  1   2    3    4    5    6    7  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.